Home › Research › Topics › validity
validity
238 studies tagged validity, dated 1991-08-01 to 2026-10-29. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- A digital programme to prevent falls and improve wellbeing in people living with dementia in the community: Quantitative results from the KOKU-LITE feasibility study 2026-10-29
- Stable and Interpretable Cognitive Status Screening Using Longitudinal Wearable Data 2026-10-20
- Comorbidities of dementia in electronic health records: validation of a natural language processing app and comparison with data linkage 2026-10-19
Studies
238 studies carry this tag.
Date range
1991 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 12
- Journal of Alzheimer's disease : JAD 12
- medRxiv 12
- Research Square 11
- Alzheimer's & dementia (Amsterdam, Netherlands) 9
107 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
The median (interquartile range) test time for MARC was 401 (350-453) s. Total MARC scores were significantly worse in the MCI and ADD groups than in the NDC group (p < 0.05 and p < 0.01, respectively).
-
Sixteen semi-structured interviews were conducted with nine participants, at two-time points.
-
Well-designed and executed RCTs are needed to confirm our findings on stroke and to have more scientific evidence available for the other neurological diseases.
-
MDT-OS and ORR-LDR were weakly-to-moderately correlated with the Preclinical Alzheimer's Cognitive Composite (PACC5) (r = 0.3-0.44, p < .001) and with several other measures of episodic memory, processing speed, and executive function.
-
Our results suggest that the ki:e SB-C is an objective, scalable, and reliable indicator of cognitive decline, fit for purpose as a remote assessment in clinical early dementia trials.
-
Overall, the results suggest that ARC is reliable and valid and represents a feasible tool for assessing cognitive changes associated with the earliest stages of AD.
-
Digital therapeutics (DTx) are a subset of digital health which are often coupled with artificial intelligence (A.I.) techniques and machine learning systems.
-
Population aging brings with it cognitive impairment.
-
A total of 103 participants completed all investigations and were included in the analysis.
-
The rapidly increasing worldwide population of older adults, along with the increasing prevalence of cognitive impairment and dementia in this population, is a growing health-care problem.
-
This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI.
-
BrainCheck was able to distinguish between diagnoses of dementia, MCI, and NC, providing a potentially reliable tool for early detection of cognitive impairment.
-
48/100
Mobile-health applications can be used to deliver timely and personalized health information to family and friends of chronically ill adults living in the community.
-
Longitudinal cognitive testing is essential for developing novel preventive interventions for dementia and Alzheimer's disease; however, the few available tools have significant practice effect and depend on an external evaluator.
-
The SLS is a valid and reliable self-administered memory test that shows promise for remote assessment of aging and neurodegenerative disorders.
-
CVRF prevalence was 62.8% (n=150) for high cholesterol, 45.2% (n=108) for hypertension, 10.9% (n=26) for atrial fibrillation, and 7.5% (n=18) for diabetes.
-
We found patient and care partner input to be critical throughout the development process for early identification of design and usability issues and for identifying solutions not previously considered by our research team.
-
Overall, individuals improved on all C3 measures over 12 months (β = 0.23, 95% CI [0.21-0.25], p < 0.001), but improvement over the first 3 months was greatest (β = 0.68, 95% CI [0.59-0.77], p < 0.001), suggesting stronger PE over initial repeated exposures.
-
To the best of our knowledge, this will be the first systematic review and meta-analysis of narrowly defined CCT across clinical populations with depression.
-
Alzheimer's disease (AD) is a progressive, multifactorial, chronic, neurodegenerative disease with high prevalence and limited therapeutic options, making it a global health crisis.
-
The AD group performed significantly lower on the associative learning (p = 0.01) and associative memory assessments (p = 0.002), than the HC and AR groups.
-
In MCI subjects, the NCPT composite is significantly correlated with both a composite measure of established tests (r = 0.78, p < 0.0001) as well as with the ADAS-Cog (r = -0.55, p < 0.0001).
-
For the reproducibility, identical P-values and slope estimates were found with both digital biomarkers and neuropsychological test measures between the previous and current studies.
-
Affective computing (also referred to as artificial emotion intelligence or emotion AI) is the study and development of systems and devices that can recognize, interpret, process, and simulate emotion or other affective phenomena.
-
33 Chinese- and 117 English-speaking older adults who received a diagnosis of normal cognition or mild cognitive impairment at consensus were included in the data analysis.
-
The One Card Learning Test (OCL80) from the Cogstate Brief Battery-a digital cognitive test used both in-person and remotely in clinical trials and in healthcare contexts to inform health decisions-has shown high sensitivity to changes in memory in early Alzheimer's disease (AD).
-
Detecting early signs of cognitive decline is crucial for early detection and treatment of Alzheimer's Disease.
-
BRANCH reliably captures meaningful cognitive information remotely, suggesting promise as a digital cognitive marker sensitive early in the AD trajectory.
-
We conclude with an interdependent list of challenges that must be collaboratively addressed before these endpoints are widely adopted.
-
Alzheimer's Disease (AD) is one of the most prevalent neurodegenerative chronic diseases.
-
Between March 1, 2016, and March 12, 2020, 383 patients were enrolled and randomly assigned to the intervention or control group.
-
COVID-19 has caused obstacles in continuing normal life almost everywhere in the world by causing the implementation of social distancing and eventually imposing the lockdown.
-
The ICA demonstrated convergent validity with MoCA (Pearson r=0.58, p<0.0001) and ACE (r=0.62, p<0.0001).
-
There is a pressing need to capture and track subtle cognitive change at the preclinical stage of Alzheimer's disease (AD) rapidly, cost-effectively, and with high sensitivity.
-
Access to affordable, objective and scalable biomarkers of brain function is needed to transform the healthcare burden of neuropsychiatric and neurodegenerative disease.
-
Conventional neuropsychological assessments for Alzheimer's disease are burdensome and inaccurate at detecting mild cognitive impairment and predicting Alzheimer's disease risk.
-
Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries.
-
Participants in the experimental group had better overall subjective memory, subjective retrospective memory and global quality of life, with fewer depressive symptoms than those in the control group 3 months following the program.
-
The study aimed to investigate the relationship between mobile phone use and cognitive impairment using the data of the Prevention and Intervention on Neurodegenerative Disease for Elderly in China (PINDEC) survey.
-
Our study is well placed to evaluate the clinical utility of RMT assessments.
-
Telemedicine is well received among patients and care partners, but successful delivery incorporates support staff and the care partners to navigate technologies.
-
Wearable devices have found numerous applications in healthcare ranging from physiological diseases, such as cardiovascular diseases, hypertension and muscle disorders to neurocognitive disorders, such as Parkinson’s disease, Alzheimer’s disease and other psychological diseases.
-
Health-monitoring technologies for automatically detecting the early signs of Alzheimer's disease (AD) have become increasingly important.
-
Variability in step velocity and cadence had the highest predictive utility in identifying individuals with mild AD.
-
55/100
The BHA has excellent performance characteristics in detecting cognitive impairment including dementia and MCI in a Hispanic population in Cuba and outperformed the MoCA.
-
The data show that dementia research is exponentially developing following the evolution of widespread use of computer science.
-
61/100
These findings provide support for both the feasibility and validity of C3 and computerized cognitive outcomes more generally in AD secondary prevention trials.
-
MemTrax can effectively detect both clinically diagnosed MCI and AD with better accuracy as compared to the MoCA based on AUCs in a Chinese cohort.
-
We applied our procedure to real-world data which include longitudinal in-home monitored walking speed.
-
Previous studies have shown that the diagnostic performance of digital cognitive tests is comparable with that of conventional paper-and-pencil tests.
From across this tag
5 of the 238 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 5. The same 5 appear here every time.
- Enhancing cognitive control in amnestic mild cognitive impairment via at-home non-invasive neuromodulation in a randomized trial
- Computerized cognitive assessment in primary care to identify patients with suspected cognitive impairment
- Applying the Health Belief Model to Quantify and Investigate Expectations for Computerized Cognitive Training
- Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers
- Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies